Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Serdemetan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
JNJ-26854165 (serdemetan) has previously been reported to inhibit the function of the E3 ligase human double minute 2, and we… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Serdemetan (JNJ-26854165), an antagonist to Mdm2, was anticipated to promote the activation of p53. While regulation of p53 by… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ… Expand
  • table I
  • table II
Is this relevant?
2011
2011
Serdemetan (JNJ-26854165) is a novel tryptamine compound with antiproliferative activity in various p53 wild-type (WT) tumor cell… Expand
Is this relevant?
2011
2011
PURPOSE Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclinical… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2010
2010
e13011 Background: Serdemetan is a compound that can cause replicative stress type responses in tumor cells and it has been… Expand
Is this relevant?